1. Parkinson's disease; 2. Parkinsonś pharmacological therapy; 3. Dopamine synthesis; 4. Dopamine storage and release; 5. Dopamine oxidative deamination; 6. Dopamine methylation; 7. Dopamine oxidation to neuromelanin and neurotoxic metabolites; 8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity; 9. Preclinical model based on exogenous neurotoxins for Parkinson's disease; 10. Preclinical models based on genetic mutations associated with the familial form of Parkinsonś disease; 11. Preclinical models based on endogenous neurotoxins; 12. Conclusions
